Cargando…

Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists

Physiological changes such as hypoxia in the tumor microenvironment (TME) endow cancer cells with malignant properties, leading to tumor recurrence and rapid progression. Here, we assessed the effect of hypoxia (1% Oxygen) on the tumor suppressor Annexin A6 (AnxA6) and the response of triple-negativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Stephen D., Smith, Tunde M., Stewart, LaMonica V., Sakwe, Amos M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564279/ https://www.ncbi.nlm.nih.gov/pubmed/36230969 http://dx.doi.org/10.3390/cells11193007

Ejemplares similares

Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies
por: Korolkova, Olga Y., et al.
Publicado: (2020)

Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors
por: Widatalla, Sarrah E, et al.
Publicado: (2019)

Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells
por: Williams, Stephen D., et al.
Publicado: (2022)

Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets
por: Korolkova, Olga Y., et al.
Publicado: (2020)

Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors
por: Koumangoye, Rainelli B, et al.
Publicado: (2013)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility
por: Whalen, Diva S., et al.
Publicado: (2019)

Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer
por: Beasley, Heather K., et al.
Publicado: (2022)

Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
por: Michmerhuizen, Anna R., et al.
Publicado: (2020)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2011)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

A Cell-Based Systematic Review on the Role of Annexin A1 in Triple-Negative Breast Cancers
por: Pearanpan, Lishantini, et al.
Publicado: (2022)

The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells
por: Bolden, Adrienne, et al.
Publicado: (2012)

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?
por: Giannos, Aris, et al.
Publicado: (2015)

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies
por: Chaudhary, P, et al.
Publicado: (2014)

Inhibition of Triple-Negative Breast Cancer Cell Aggressiveness by Cathepsin D Blockage: Role of Annexin A1
por: Zóia, Mariana Alves Pereira, et al.
Publicado: (2019)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature
por: Davis, Melissa, et al.
Publicado: (2018)

Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?
por: LaCasse, Eric C.
Publicado: (2020)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
por: Luo, Jiayan, et al.
Publicado: (2016)

AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants
por: Dart, D A, et al.
Publicado: (2019)

Combined Therapy of A(1)AR Agonists and A(2A)AR Antagonists in Neuroinflammation
por: Marucci, Gabriella, et al.
Publicado: (2021)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis
por: Okano, Maiko, et al.
Publicado: (2019)

The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist
por: Li, Xaria X., et al.
Publicado: (2021)

Cheminformatics analysis of the AR agonist and antagonist datasets in PubChem
por: Hao, Ming, et al.
Publicado: (2016)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Unconventional secretion of annexins and galectins
por: Popa, Stephanie J., et al.
Publicado: (2018)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
por: Inoue, Satoshi, et al.
Publicado: (2012)

Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer
por: Sood, Neelam, et al.
Publicado: (2014)

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells
por: Hossein-Nejad-Ariani, Hanieh, et al.
Publicado: (2019)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity
por: Hornig, N. C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sut49402rvidjo7fsl0iassaot